Carter H B, Epstein J I
Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
World J Urol. 1997;15(6):359-63. doi: 10.1007/BF01300183.
Widespread prostate specific antigen (PSA) testing results in detection of prostate cancer 4-6 years earlier than possible with digital rectal examination. Twenty to thirty percent of prostate cancers detected with PSA testing (non-palpable disease) are small tumors (< 0.5cc) that may be unimportant in some men. Pre-treatment criteria that include PSA density and prostate biopsy findings provide the means to assess the significance of prostate cancer after diagnosis. This information is useful when counseling men regarding management options for non-palpable, PSA detected prostate cancer.
广泛开展前列腺特异性抗原（PSA）检测比直肠指检能提前4至6年发现前列腺癌。通过PSA检测发现的前列腺癌（不可触及的疾病）中，20%至30%是小肿瘤（<0.5立方厘米），对某些男性来说可能并不重要。包括PSA密度和前列腺活检结果在内的治疗前标准为评估前列腺癌诊断后的重要性提供了方法。在为男性提供关于不可触及的、通过PSA检测发现的前列腺癌的管理选择咨询时，这些信息很有用。
